The Best Small-Cap Stocks to Buy Now

Biotech, real estate and software dominate the list of Wall Street's best small-cap stocks to buy.

best small cap stocks
(Image credit: Getty Images)

The final quarter of 2025 and first quarter of the new year could be much more favorable for stockpickers looking for the best small-cap stocks to buy.

That might sound counterintuitive after the way small caps have underperformed during the current bull market. After all, small caps as an asset class have been a dud. They've struggled to keep up as mega-cap stocks pushed the broader market to record highs.

To recap: the broader S&P 500 is up more than 80% since the bull market's onset three years ago. The tech-heavy Nasdaq Composite more than doubled over the same span. Hurt partly by its price-weighted construction, the blue-chip Dow Jones Industrial Average gained just 55%.

From just $107.88 $24.99 for Kiplinger Personal Finance

Be a smarter, better informed investor.

CLICK FOR FREE ISSUE
https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png

Sign up for Kiplinger’s Free Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

Select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) have been fueling much of the market's gains. And so small caps – which tend to be more sensitive to the economic cycle, tariffs and interest rates – are lagging badly.

Indeed, the small-cap benchmark Russell 2000 Index is up just 41% over the past three years.

If there is a sliver of a silver lining to the Russell 2000's chronic underperformance, it's that small cap valuations look dirt cheap.

"The broadening of profits growth is finally extending into small caps," notes Jill Carey Hall, an equity and quant strategist at BofA Securities. "Small caps continue to trade at about a 30% historical discount to large caps, implying likelihood of outperformance over the long-term. We remain constructive on small caps for now."

And with the Federal Reserve expected to enact several cuts to the federal funds rate in the coming quarters, small caps should have at least one catalyst behind them.

Our methodology for finding the best small-caps stocks to buy

In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.

Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell.

Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.

In other words, lower scores are better than higher scores.

We further limited ourselves to stocks with at least 12 Strong Buy recommendations to ensure adequate analyst coverage and sample size. Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data to find the best stocks to buy.

Our screen of the Street's top small-cap stocks served up a list dominated by the health care sector, mostly pharmaceutical and biotechnology companies.

That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.

In other cases, some of these names – a gaming stock and real estate investment trust (REIT), for instance – might just surprise you.

And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.

Swipe to scroll horizontally
Wall Street's top-rated small-cap stocks

Company (Ticker)

Analysts' consensus recommendation score

Subsector

Analysts' consensus recommendation

Spyre Therapeutics (SYRE)

1.14

Biotechnology

Strong Buy

Denali Therapeutics (DNLI)

1.16

Biotechnology

Strong Buy

Waystar Holding (WAY)

1.19

Health Care Technology

Strong Buy

Xenon Pharmaceuticals (XENE)

1.21

Biotechnology

Strong Buy

Genius Sports (GENI)

1.22

Casinos & Gaming

Strong Buy

Janux Therapeutics (JANX)

1.22

Biotechnology

Strong Buy

Axsome Therapeutics (AXSM)

1.25

Pharmaceuticals

Strong Buy

Wave Life Sciences (WVE)

1.27

Pharmaceuticals

Strong Buy

Kymera Therapeutics (KYMR)

1.27

Biotechnology

Strong Buy

Riot Platforms (RIOT)

1.28

Application Software

Strong Buy

Avidity Biosciences (RNA)

1.28

Biotechnology

Strong Buy

Braze (BRZE)

1.30

Application Software

Strong Buy

Biohaven (BHVN)

1.33

Biotechnology

Strong Buy

Guardant Health (GH)

1.35

Health Care Services

Strong Buy

BridgeBio Pharma (BBIO)

1.37

Biotechnology

Strong Buy

Essential Properties Realty Trust (EPRT)

1.37

Diversified REITs

Strong Buy

Arcellx (ACLX)

1.39

Biotechnology

Strong Buy

Privia Health Group (PRVA)

1.40

Health Care Services

Strong Buy

IDEAYA Biosciences (IDYA)

1.42

Biotechnology

Strong Buy

NetSTREIT (NTST)

1.50

Retail REITs

Strong Buy

Related content

Dan Burrows
Senior Investing Writer, Kiplinger.com

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.

A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.

Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.

In his current role at Kiplinger, Dan writes about markets and macroeconomics.

Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.

Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.